(Q38050151)

27 August 2017

title

Humalog (lispro) for type 2 diabetes (English)

1 reference

27 August 2017

1 reference

type 2 diabetes

9 December 2023

Annalisa Capuano

2

0 references

author name string

Katherine Esposito

series ordinal

1

1 reference

27 August 2017

Dario Giugliano

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1541-1550

1 reference

IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

National trends in treatment of type 2 diabetes mellitus, 1994-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

The proliferating role of insulin and insulin-like growth factors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

HbA1c targets for type 2 diabetes: How many, …how far!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.728584

10.1517/14712598.2012.728584

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference